Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive Patients (WONDeR)

November 30, 2016 updated by: GlaxoSmithKline

A Multi-center, Observational, Cross-sectional Study to Evaluate CVD Risk Factors in Korean Hypertensive Patients

The purpose of this study is investigating the proportion of Cardiovascular disease risk factors of hypertensive patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Primary endpoint: To evaluate the Proportion of patients with Cardiovascular disease high risk factors

Secondary endpoint: To evaluate the Proportion of patients with Cardiovascular disease risk factors, To evaluate the Proportion of patients with Cardiovascular disease, To evaluate Target blood pressure achievement rate according to the proportion of Cardiovascular disease risks

Study Type

Observational

Enrollment (Actual)

3109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Korea, Diagnosed hypertensive patient

Description

Inclusion Criteria:

  • Essential hypertensive patient no less than 18 yeas old
  • Patient who gave informed consent form

Exclusion Criteria:

  • Patient was diagnosed as secondary hypertension
  • Patient who have white-coat hypertension

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hypertension
Subject who meet eligible criteria
Other: Blood Sampling
Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
Other Names:
  • Blood sampling for cardiovascular disease risk

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with cardiovascular disease high risk factors
Time Frame: 6years, average duration of hypertension
Between patients with essential hypertension
6years, average duration of hypertension

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with Cardiovascular disease risk factors
Time Frame: 6years, average duration of hypertension
Between patients with essential hypertension
6years, average duration of hypertension
Proportion of patients with Cardiovascular disease
Time Frame: 6years, average duration of hypertension
Between patients with essential hypertension
6years, average duration of hypertension
Target Blood Pressure achievement rate according to the proportion of Cardiovascular disease risks
Time Frame: 6years, average duration of hypertension
Between patients with essential hypertension
6years, average duration of hypertension

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (Actual)

January 1, 2011

Study Completion (Actual)

January 1, 2011

Study Registration Dates

First Submitted

May 5, 2011

First Submitted That Met QC Criteria

May 26, 2011

First Posted (Estimate)

May 30, 2011

Study Record Updates

Last Update Posted (Estimate)

December 1, 2016

Last Update Submitted That Met QC Criteria

November 30, 2016

Last Verified

November 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 114619

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Blood Sampling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe